Pioneering

vaccines that

transform

lives.

Immunomic Therapeutics, Inc.

LAMP-Vax for General Oncology

Presentation Outline

1. Immunomic Therapeutics: corporate overview

2. Unmet need in cancer immunotherapy landscape

3. How cancer vaccines & LAMP-Vax™ in particular is a

potential solution to current shortcomings

4. Existing data & current focus for LAMP-Vax in immuno-

oncology

5. Partnering objectives and timeline

Immunomic Therapeutics: Company Overview

Immunomic Therapeutics

• Privately held company, based in Rockville MD, founded in 2006

• LAMP-Vax™ (Lysosomal Associated Membrane Protein) platform

• Strong preclinical & clinical results in allergy and cancer

• Funded by angels & family offices; less than $20 million

• In 2015, created over $317 million in licensing revenue; 2 deals with

Astellas, and over a 5-6x return for investors

• Applying LAMP-Vax to cancer immunotherapy to combat cancer &

broaden immunotherapy use and to animal health applications

Corporate Overview: Successful Platform Technology Company

Immunomic Therapeutics

Technically focused company ~30 employees

• Over ½ employees in R&D and PD + seasoned management

• In-house clinical trial & GMP experience & capabilities

Successful working relationship with pharma 3 years into license:

• ASP-0892 (Peanut Ph I – granted FDA Fast Track designation)

• ASP-4070 (Japanese red cedar) program in Ph II clinical studies

Delivery of GMP grade vaccine for clinical studies

R&D/PD/Clinical capabilities drive LAMP-Vax forward in cancer immunotherapy

• R&D, Process Development & Manufacturing Management

Strong Management & Capabilities – Prime Partner for Pharma

R&D, PD and Clinical Dev Process

From Idea to POC in Animals in a Year

R&D, PD and Clinical Dev Process

Capabilities Through end of Phase II

Unmet Need Within Current Immunotherapy Landscape

LAMP-Vax in the Immuno-Oncology Landscape

Solution: Cancer Vaccines to Generate High Affinity T Cell Responses

Inflamed Excluded Infiltrate Immune Desert

T cells infiltrated,

but non-functional

T cells accumulated but

not efficiently infiltrated

T cells absent from

tumor and periphery

1 http://dx.doi.org/10.1016/j.immuni.2013.07.012

Left: Inflamed tumor, where checkpoint inhibition is active.

Center: Inflamed tumor but microenvironment may prevent immune system from getting in.

Right: No immune response present, “cold tumor”.

LAMP-Vax has the potential advantage in creating high affinity CD8 by supporting helper T cells, which could add

therapeutic value to each of these categories/states.

LAMP-Vax Platform

The LAMP-Vax Platform: Mode of Action

Th1 Response and Relevance

The LAMP-Vax Platform MOA & Results

LAMP-Vax Mode of Action

• Effect presentation to the immune system via professional antigen presenting cells

• Synthesize native proteins directly in the cell

• Trafficking motif moves chimeric proteins into the MHC-II compartment in a protected

format with high efficiency

Results in:

• Antigen presentation to the MHC-II without any folding or pre-digestion issues

• Broad immune response; helper T cells elicit a humoral response while also

expanding and improving the activity of CD8+ cells

• Compatible with other therapeutics

Strengthens Immune Response and Creates Memory

LAMP-Vax Modalities, Existing Data & Current Application Areas

LAMP-Vax Platform for Oncology

A Stand Alone Platform and Additive to Other Platforms

Multiple Antigens

Viral

Self/Overexpressed

Cancer Testes

Neo antigen

Multiple Modalities

Autologous Dendritic

Cell

Plasmid DNA

mRNA (naked or

liposomal)

Combination (e.x. pDNA

with Adeno)

Multiple Tumors

GBM

AML (Blood)

Breast/Ovarian

Prostate

ITI is exploring and exploiting the various ways that the flexible LAMP-Vax

platform technology is applicable and complementary to other approaches.

Duke pp65-LAMP DC Clinical Studies

PFS & OS Data for pp65-LAMP DCs + RT + TMZ

Overall Survival of pp65-LAMP DC Therapy (months)

0 10 20 30 40 50 60 70

15161718

420

692

2219

121142313

78

245

123

1011

OS from diagnosis

Pa

tie

nt

Nu

mb

er

pp65-LAMP, no Td/GM-CSF

pp65-LAMP, Td prime

pp65-LAMP, GM-CSF

Alive as of Sept. 9, 2016

Historical OS, 20 months1

Sources: Mitchell DA et al., 2015. Nature | Vol 51 9 | 19 March and Batich KA et al., 2017. Clin Cancer Res; 23(8) April 15,

2017. 1 ITI analysis of GBM TCGA dataset, restricted to KPS>80 receiving RT + TMZ

Current LAMP-Vax Focused Strategy

3 Key Approaches Currently Being Tested

Antigen Categories & Programs

Viral Antigens

Additional studies in

progress with CMV &

others (eg. HPV)

Ca Testes &

Overexpressed

Neo Antigens

Various targets being

explored, including cancer

testes ags., various

approaches (e.g. epitope)

LAMP-Vax: enhanced

immune response (e.x. CD4

epitopes) & quick TAT

platform

Phase I data available,

Phase II ongoing, new

animal data in progress

New animal model data

available, more in by

Q2 2017

Data in animals being

generated in-house & in

collaboration: available Q2/3

2017

In house and under collaboration tested in models & humans in multiple

tumors.

Robust Product Pipeline

Allergy, Animal Health, Oncology

DesignAnimal POC

Pre-Clinical

Ph. I Ph. II Ph. III Partner / Collaborator

ALLERGY VACCINE THERAPY

ASP-4070 • Japanese red cedar Astellas

ASP-0892 • Peanut Astellas

LAMP-Vax • Undisclosed allergy Astellas

CAD-LAMP-Vax • Allergy in dogs Internal

ONCOLOGY IMMUNOTHERAPY

AST-VAC1 • AML BioTime / Asterias

GBM-LAMP-Vax • Glioblastoma UF/Duke/Annias

AST-VAC2 • NSCLC BioTime / Asterias

Viral Ag LAMP-Vax UF & Internal

Epitope LAMP-Vax Internal

Neoantigen LAMP-Vax Internal

CA Ag LAMP-Vax Internal

Conclusions

Cancer Immuno-Oncology

Market Too Large to Miss

Oncology drug market

• $85B in 20151

• $120B - $135B by 20212

Cancer immunotherapy market

• estimates are up to $30-40B by 20233

• Immunotherapy drugs will be treating 60% of cancers in next 10

years

Cancer vaccines market

• $7.5B by 20224

• Cancer Vaccines market growing in excess of 30% per year

High pharma interest in oncology market

• 2016 Average Deal Value: over $1B

• 2016 Average Upfront Payment: over $300M

ITI will leverage the foundation

that it has on high unmet need

Ph I/II LAMP vaccines in

prostate, AML, melanoma and

GBM

62

85

127

0

20

40

60

80

100

120

140

160

2010 2015 2021

Bill

ion

s, U

SD

Market Growth of Oncology Drugs

1 – source: Bloomberg

2 – source: IMSHealth

3 – source: GlobalData Pharma eTrack

4 – source: GBI Research; includes HPV vaccines

Seeking Business Development Opportunities

Summary, Timeline & Objectives

LAMP-Vax in a Phase II study in GBM and Phase I in NSCLC.

Testing in animal models to demonstrate potential POC in

various tumor types in 2017.

Data/information available under CDA in 2017:

• Existing body of Phase I and II data employing LAMP

• Mechanism of action (MoA) data (support from allergy work)

• Animal data with candidate LAMP-Vax in various tumor

models w/ preferred platform for LAMP-Vax.

• Additional information (IP, regulatory, manufacturing)

In 2017, initiating formal BD discussions with Pharma for

transaction/collaboration in oncology and animal health.

Preferred Transactions:

• Exclusive WW rights for all oncology applications OR

• Focus on specific cancer(s), products OR geography

• Willing to consider alternatives

LAMP-Vax Nucleic Acid Vaccine Platform:

Fulfills an Unmet Need in Cancer

Immunotherapy

Could activate Th1 Type Tumor Specific T

cell responses at the tumor: turn cold

tumors “hot.”

Strong foundation with LAMP-Vax

specifically in allergy & oncology

Growth since two significant licenses with

Astellas Pharma in 2015

Immunomic: prime target for partnerships

with pharmaceutical companies in

immuno-oncology

Conclusions

LAMP-Vax and Cancer Immunotherapy

Thank You

Headquarters & Lab: Rockville, MD

TEL: 301-968-3501

www.immunomix.com

twitter.com/immunomix

Sia Anagnostou

Sr. Director of Corporate Development

Immunomic Therapeutics, Inc.

email: sia@immunomix.com

Tel: 717 327 1822